CholBiome®

with L. plantarum LP ...





CholBiome®

CholBiome® is a scientifically backed food supplement that helps to maintain cholesterol levels, and reduce blood pressure, promoting overall heart wellness.

It harnesses the power of the microbiome through the patented probiotic *Lactobacillus plantarum* LP_{LDL}® which has been found not only to reduce LDL but also boost HDL cholesterol levels, through natural means.

Available in boxes or bottles of 30 Capsules.

Directions for use

Only one tablet of CholBiome® must be taken once daily after the main meal for full health benefits.

-M- GMO FREE

→ GOOD MANUFACTURING PRACTICE (GMP)


ALLERGEN FREE

√ VFGAN

About the Gut-Liver Axis

The liver and the microorganisms of the gut microbiome have an intense functional and bidirectional communication known as the *Gut-Liver Axis*. In this metabolic cooperation, the liver produces and releases bile salts influencing cholesterol metabolism.

It is now known that certain microbes, such as LP_{LDL}®, are able to metabolise bile salts, releasing metabolites that interact with the human body. This activity can help regulate high cholesterol and blood pressure and is involved in the regulation of physiological processes such as glucose regulation, vitamin metabolism and liver function.





About Lactobacillus plantarum LP Page 8

LP_{LDL}® is a naturally-occurring strain of the bacterial species Lactobacillus plantarum. Lactobacilli are common components of the human intestinal microbiome and have traditionally been used as probiotics1.

LP, was selected using OptiBiotix's OptiScreen® proprietary technology platform from a collection of over 4,000 microbial candidates for its outstanding capacity to hydrolyse bile salts. This activity is crucial for bacterial survival in the harsh conditions of the intestine and mediates the mechanism of action from LP_{LDL}.

Clinical Studies

An independent, double blind, randomised, placebocontrolled human study with LP_{LDL}® was carried out by the University of Reading in the UK, with 49 normal to mildly hypercholesterolemic adults.

Volunteers were administered a daily dose of 4x109 CFU of $LP_{LDL}^{\ \ \ \ \ \ }$ or placebo. In the active group, $LP_{LDL}^{\ \ \ \ \ \ }$ was shown to be completely safe and well tolerated with statistically significant changes observed in multiple CVD biomarkers:

12-week results of LP_{LDL}® vs Placebo:



University of Reading: Costabile et al., 2017

6-week results of LP_{IDI}® vs Placebo:



In a follow-up independent, double blind, randomised, placebo-controlled parallel human study carried out by the University of Roehampton in the UK, 16 hypercholesterolemic adults consumed 4x10° CFU encapsulated LP_{IDI}® or placebo.

Volunteers were instructed to take this daily across 6 weeks, followed by a 3-week washout period. LP_{IDI}® intake resulted in statistically significant reductions in multiple CVD risk biomarkers as early as 3 weeks, which decreased even further at the end of the 6-week treatment.

To find out more please contact ProBiotix on:



IpIdI.com

For media enquiries please contact:

PHD Marketing | Tel: +44 1977 708643

Email: hello@phdmarketing.co.uk | phdmarketing.co.uk

